

# Hildegund C J Ertl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2296364/publications.pdf>

Version: 2024-02-01

80  
papers

5,897  
citations

101543

36  
h-index

74163

75  
g-index

82  
all docs

82  
docs citations

82  
times ranked

6455  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effect of Rapamycin and Ibrutinib on Antibody Responses to Adeno-Associated Virus Vector-Mediated Gene Transfer. <i>Human Gene Therapy</i> , 2022, 33, 614-624.	2.7	16
2	Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2022, 77, 525-538.	3.7	16
3	A One Medicine Mission for an Effective Rabies Therapy. <i>Frontiers in Veterinary Science</i> , 2022, 9, 867382.	2.2	4
4	COVID-19 Vaccines Based on Adenovirus Vectors. <i>Trends in Biochemical Sciences</i> , 2021, 46, 429-430.	7.5	24
5	Vaccine-induced ICOS+CD38+ circulating Tfh are sensitive biosensors of age-related changes in inflammatory pathways. <i>Cell Reports Medicine</i> , 2021, 2, 100262.	6.5	26
6	PPAR $\alpha$ Agonist Fenofibrate Enhances Cancer Vaccine Efficacy. <i>Cancer Research</i> , 2021, 81, 4431-4440.	0.9	17
7	Hepatitis B virus polymerase-specific T cell epitopes shift in a mouse model of chronic infection. <i>Virology Journal</i> , 2021, 18, 242.	3.4	2
8	The Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer. <i>Molecular Therapy</i> , 2020, 28, 771-783.	8.2	44
9	Towards rabies elimination in the Asia-Pacific region: From theory to practice. <i>Biologicals</i> , 2020, 64, 83-95.	1.4	25
10	Novel Rabies Vaccines. , 2020, , 155-180.		0
11	New human rabies vaccines in the pipeline. <i>Vaccine</i> , 2019, 37, A140-A145.	3.8	22
12	New Rabies Vaccines for Use in Humans. <i>Vaccines</i> , 2019, 7, 54.	4.4	32
13	Avoiding preventable deaths: The scourge of counterfeit rabies vaccines. <i>Vaccine</i> , 2019, 37, 2285-2287.	3.8	22
14	Prime-boost vaccination with recombinant protein and adenovirus-vector expressing <i>Plasmodium vivax</i> circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge. <i>Scientific Reports</i> , 2018, 8, 1118.	3.3	31
15	Immune response to influenza vaccination in the elderly is altered by chronic medication use. <i>Immunity and Ageing</i> , 2018, 15, 19.	4.2	23
16	Additional Progress in the Development and Application of a Direct, Rapid Immunohistochemical Test for Rabies Diagnosis. <i>Veterinary Sciences</i> , 2018, 5, 59.	1.7	17
17	Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1533-1544.	4.2	7
18	Correlates of Protection Against SIVmac251 Infection in Rhesus Macaques Immunized With Chimpanzee-Derived Adenovirus Vectors. <i>EBioMedicine</i> , 2018, 31, 25-35.	6.1	13

#	ARTICLE	IF	CITATIONS
19	Rabies Vaccines. , 2018, , 918-942.e12.		8
20	The effect of timing of influenza vaccination and sample collection on antibody titers and responses in the aged. <i>Vaccine</i> , 2017, 35, 3700-3708.	3.8	30
21	Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. <i>Cancer Cell</i> , 2017, 32, 377-391.e9.	16.8	419
22	Pre-exposure rabies prophylaxis: a systematic review. <i>Bulletin of the World Health Organization</i> , 2017, 95, 210-219C.	3.3	89
23	Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors. <i>Oncotarget</i> , 2016, 7, 23282-23299.	1.8	81
24	Vaccine Design: Replication-Defective Adenovirus Vectors. <i>Methods in Molecular Biology</i> , 2016, 1404, 329-349.	0.9	5
25	A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products. <i>Human Gene Therapy Methods</i> , 2016, 27, 187-196.	2.1	3
26	Rapid, Efficient, and Modular Generation of Adenoviral Vectors via Isothermal Assembly. <i>Current Protocols in Molecular Biology</i> , 2016, 113, 16.26.1-16.26.18.	2.9	12
27	Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140. <i>Aids</i> , 2016, 30, 2405-2414.	2.2	14
28	Race-related differences in antibody responses to the inactivated influenza vaccine are linked to distinct pre-vaccination gene expression profiles in blood. <i>Oncotarget</i> , 2016, 7, 62898-62911.	1.8	56
29	AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 15029.	4.1	59
30	Activated CD4 <sup>+</sup> CCR5 <sup>+</sup> T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 518-523.	7.1	88
31	Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer. <i>Journal of Innate Immunity</i> , 2015, 7, 302-314.	3.8	62
32	BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine. <i>Oncotarget</i> , 2015, 6, 19445-19455.	1.8	16
33	Survivin-targeting Artificial MicroRNAs Mediated by Adenovirus Suppress Tumor Activity in Cancer Cells and Xenograft Models. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e208.	5.1	22
34	CD8+ T Cell Recognition of Epitopes Within the Capsid of Adeno-associated Virus 8-based Gene Transfer Vectors Depends on Vectors' Genome. <i>Molecular Therapy</i> , 2014, 22, 42-51.	8.2	30
35	The Effect of Adjuvanting Cancer Vaccines with Herpes Simplex Virus Glycoprotein D on Melanoma-Driven CD8+ T Cell Exhaustion. <i>Journal of Immunology</i> , 2014, 193, 1836-1846.	0.8	20
36	Enhancement of recombinant adenovirus vaccine-induced primary but not secondary systemic and mucosal immune responses by all-trans retinoic acid. <i>Vaccine</i> , 2014, 32, 3386-3392.	3.8	8

#	ARTICLE	IF	CITATIONS
37	Immunogenicity of a Prime-Boost Vaccine Containing the Circumsporozoite Proteins of Plasmodium vivax in Rodents. Infection and Immunity, 2014, 82, 793-807.	2.2	25
38	Construction and Characterization of E1- and E3-Deleted Adenovirus Vectors Expressing Two Antigens from Two Separate Expression Cassettes. Human Gene Therapy, 2014, 25, 328-338.	2.7	7
39	Circulating CXCR5+PD-1+ Response Predicts Influenza Vaccine Antibody Responses in Young Adults but not Elderly Adults. Journal of Immunology, 2014, 193, 3528-3537.	0.8	145
40	The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses. Journal of Leukocyte Biology, 2014, 96, 821-831.	3.3	15
41	Hexon-modified Recombinant E1-deleted Adenovirus Vectors as Dual Specificity Vaccine Carriers for Influenza Virus. Molecular Therapy, 2013, 21, 696-706.	8.2	22
42	Influenza Virus Specific CD8+T Cells Exacerbate Infection Following High Dose Influenza Challenge of Aged Mice. BioMed Research International, 2013, 2013, 1-14.	1.9	14
43	B cell responses to the 2011/12-influenza vaccine in the aged. Aging, 2013, 5, 209-226.	3.1	12
44	Self-complementary AAVs Induce More Potent Transgene Product-specific Immune Responses Compared to a Single-stranded Genome. Molecular Therapy, 2012, 20, 572-579.	8.2	45
45	Correlates of relative resistance against low-dose rectal simian immunodeficiency virus challenges in peripheral blood mononuclear cells of vaccinated rhesus macaques. Journal of Leukocyte Biology, 2012, 93, 437-448.	3.3	6
46	The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood, 2011, 117, 6459-6468.	1.4	187
47	Capsid-specific T-cell Responses to Natural Infections With Adeno-associated Viruses in Humans Differ From Those of Nonhuman Primates. Molecular Therapy, 2011, 19, 2021-2030.	8.2	68
48	Effect of Preexisting Immunity to Adenovirus on Transgene Product-Specific Genital T Cell Responses on Vaccination of Mice With a Homologous Vector. Journal of Infectious Diseases, 2011, 203, 1073-1081.	4.0	9
49	Robust genital gag-specific CD8 <sup>+</sup> T cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV-1 gag. European Journal of Immunology, 2010, 40, 3426-3438.	2.9	12
50	Targeting inhibitory pathways in cancer immunotherapy. Current Opinion in Immunology, 2010, 22, 385-390.	5.5	28
51	An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nature Protocols, 2010, 5, 1775-1785.	12.0	58
52	Augmentation of Primary Influenza A Virus-Specific CD8+ T Cell Responses in Aged Mice through Blockade of an Immunoinhibitory Pathway. Journal of Immunology, 2010, 184, 5475-5484.	0.8	25
53	A Universal Influenza A Vaccine Based on Adenovirus Expressing Matrix-2 Ectodomain and Nucleoprotein Protects Mice From Lethal Challenge. Molecular Therapy, 2010, 18, 2182-2188.	8.2	56
54	Simian recombinant adenovirus delivered by the mucosal route modulates $\gamma\delta$ T cells from murine genital tract. Vaccine, 2010, 28, 4600-4608.	3.8	8

#	ARTICLE	IF	CITATIONS
55	Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. <i>Journal of Leukocyte Biology</i> , 2009, 86, 779-793.	3.3	14
56	Potentiating vaccine immunogenicity by manipulating the HVEM/BTLA pathway and other co-stimulatory and co-inhibitory signals of the immune system. <i>Hum Vaccin</i> , 2009, 5, 6-14.	2.4	10
57	A Preclinical Animal Model to Assess the Effect of Pre-existing Immunity on AAV-mediated Gene Transfer. <i>Molecular Therapy</i> , 2009, 17, 1215-1224.	8.2	41
58	Novel Vaccines to Human Rabies. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e515.	3.0	63
59	New Insights on Adenovirus as Vaccine Vectors. <i>Molecular Therapy</i> , 2009, 17, 1333-1339.	8.2	229
60	Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. <i>Vaccine</i> , 2009, 27, 5837-5845.	3.8	44
61	Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against <i>Plasmodium berghei</i> . <i>European Journal of Immunology</i> , 2008, 38, 732-741.	2.9	95
62	Effect of Preexisting Immunity to Adenovirus Human Serotype 5 Antigens on the Immune Responses of Nonhuman Primates to Vaccine Regimens Based on Human- or Chimpanzee-Derived Adenovirus Vectors. <i>Journal of Virology</i> , 2007, 81, 6594-6604.	3.4	172
63	A CD46-binding Chimpanzee Adenovirus Vector as a Vaccine Carrier. <i>Molecular Therapy</i> , 2007, 15, 608-617.	8.2	34
64	Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. <i>Blood</i> , 2007, 110, 1916-1923.	1.4	190
65	CD8+ T-cell responses to adeno-associated virus capsid in humans. <i>Nature Medicine</i> , 2007, 13, 419-422.	30.7	629
66	Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing. <i>Virology</i> , 2007, 367, 156-167.	2.4	53
67	Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. <i>Journal of Clinical Investigation</i> , 2007, 117, 3958-70.	8.2	76
68	Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa. <i>Emerging Infectious Diseases</i> , 2006, 12, 1596-1599.	4.3	157
69	Random migration precedes stable target cell interactions of tumor-infiltrating T cells. <i>Journal of Experimental Medicine</i> , 2006, 203, 2749-2761.	8.5	201
70	A Chimpanzee-Origin Adenovirus Vector Expressing the Rabies Virus Glycoprotein as an Oral Vaccine against Inhalation Infection with Rabies Virus. <i>Molecular Therapy</i> , 2006, 14, 662-672.	8.2	53
71	Dendritic Cell Maturation, but Not CD8+ T Cell Induction, Is Dependent on Type I IFN Signaling during Vaccination with Adenovirus Vectors. <i>Journal of Immunology</i> , 2005, 175, 6032-6041.	0.8	67
72	Adenoviruses as vaccine vectors. <i>Molecular Therapy</i> , 2004, 10, 616-629.	8.2	564

#	ARTICLE	IF	CITATIONS
73	Management of Rabies in Humans. <i>Clinical Infectious Diseases</i> , 2003, 36, 60-63.	5.8	217
74	Induction of CD8+ T Cells to an HIV-1 Antigen through a Prime Boost Regimen with Heterologous E1-Deleted Adenoviral Vaccine Carriers. <i>Journal of Immunology</i> , 2003, 171, 6774-6779.	0.8	107
75	Mucosally Delivered E1-Deleted Adenoviral Vaccine Carriers Induce Transgene Product-Specific Antibody Responses in Neonatal Mice. <i>Journal of Immunology</i> , 2003, 171, 4287-4293.	0.8	34
76	A Simian Replication-Defective Adenoviral Recombinant Vaccine to HIV-1 Gag. <i>Journal of Immunology</i> , 2003, 170, 1416-1422.	0.8	193
77	Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene Product. <i>Journal of Virology</i> , 2002, 76, 2667-2675.	3.4	186
78	Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. <i>Journal of General Virology</i> , 2002, 83, 151-155.	2.9	57
79	Replication-Defective Vector Based on a Chimpanzee Adenovirus. <i>Journal of Virology</i> , 2001, 75, 11603-11613.	3.4	253
80	T helper cell epitope of rabies virus nucleoprotein defined by tri- and tetrapeptides. <i>European Journal of Immunology</i> , 1991, 21, 1-10.	2.9	51